Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
|
|
- Mariah Fletcher
- 5 years ago
- Views:
Transcription
1 280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology, Central Hospital Bolzano, Bolzano, Italy. BACKGROUND. Human papillomavirus (HPV) testing has become part of cervicovaginal diagnostics in many laboratories. False-negative HPV results, even if rare, are potentially relevant clinically, particularly when testing is used alone. In this study, the authors investigated the occurrence and causes of abnormal cervicovaginal cytologies with negative HPV testing. METHODS. The study was performed on 4130 liquid-based cytology (LBC) specimens from 2918 women who had abnormal cervical cytology or colposcopy or a history of abnormal cervical smear. HPV testing with Hybrid Capture II was repeated in LBC specimens with obviously atypical cytology (squamous intraepithelial lesion or abnormal squamous cells, cannot exclude high-grade lesion) and initial negative test results. The results were compared with the follow-up results and with the cytologic features of the specimens. RESULTS. Of 4130 LBC specimens, 94 (2.28%) showed obviously abnormal cells despite negative HPV results, and 50 of those 94 samples (53.19%) were HPVpositive on a repeated testing of the same specimen. Histologic follow-up showed high-grade intraepithelial lesion or carcinoma in 10 specimens that initially were negative for HPV. Eight of those samples were HPV-positive on testing repetition. Both specimens that had persistently negative results had poor-quality cytologic samples at revision. CONCLUSIONS. High-grade lesions may be identified in the follow-up of HPV-negative specimens with abnormal cytology. Testing repetition in patients with discordant cytology may prevent most potentially clinically relevant false-negative HPV results. Cancer (Cancer Cytopathol) 2007;111: Ó 2007 American Cancer Society. KEYWORDS: human papillomavirus, Hybrid Capture II, liquid-based cytology, ThinPrep. We thank Ventana Italy for supplying the human papillomavirus testing kit free of charge and Ms. Alessandra Spada and Mr. Hubert Dorfmann for helping collect the cases. Address for reprints: Giovanni Negri, MD, Department of Pathology, Central Hospital Bolzano, Via Boehler 5, Bolzano, Italy; Fax: (011) ; ginegri@gmail.com Received February 22, 2007; revision received May 19, 2007; accepted May 22, Human papillomavirus (HPV) testing has become part of routine cervicovaginal diagnostics in many laboratories. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study 1 demonstrated the utility of HPV testing for the triage of women with abnormal squamous cells (ASC), and the possibility of replacing cytology-based, primary screening with molecular techniques has been suggested by several authors. 2 5 Although the scenario of cervical cancer prevention is changing because of the introduction of HPV vaccines, HPV testing still will have several applications, including the follow-up of women who already have undergone vaccination. Among testing techniques, Hybrid Capture II (HCII) (Digene, Gaithersburg, Md) is one of the most widespread because of its simplicity and high sensitivity. When combined with liquid-based ª 2007 American Cancer Society DOI /cncr Published online 27 August 2007 in Wiley InterScience (
2 CV Cytology With Discordant HPV Testing/Negri et al. 281 cytology (LBC), HPV testing with HCII can be useful for the interpretation of troublesome cases without the need for recalling the woman. 1,6 With LBC, only a part of the sampled cells is used for the cytologic slides, and previous studies have indicated that HPV testing with HCII on the residual cell suspension has high sensitivity comparable to that of polymerase chain reaction (PCR) 7 9 and high interlaboratory reproducibility. 10,11 However, false-negative HPV testing can occur. In a previous study, we reported that false-negative HPV results with HCII on LBC specimens may be caused by insufficient cellularity of the specimen. 12 One other recent study indicated that false-negative HCII results may occur because of a low HPV DNA load. 13 Zuna et al. 14 observed in their study that from 3% to 11% of low-grade squamous intraepithelial lesions (LSILs) were negative for HPV but that from 12% to 32% of those lesions turned HPV-positive at the successive follow-up test. In that study, however, subsequent testing was performed on different samples. Taking into consideration the possibility of false-negative results becomes important in cases of obviously abnormal cytology and negative HPV tests. Even if they are rare, those apparently false-negative results may have important clinical consequences and may cause distrust in molecular techniques. In the current study, HPV testing with HCII was repeated in 94 ThinPrep specimens that had abnormal cytology immediately after an initial negative test. Results were compared with follow-up results, and cytologies were analyzed in an attempt to clarify the cause of the discordance. MATERIALS AND METHODS During the period from 2002 to 2004, HPV testing with HCII was performed on residual cell suspensions of 4130 ThinPrep specimens from 2918 women. Testing was routinely performed because of the presence of atypical squamous cells (ASC) in the LBC or was requested by the woman s gynecologist because of abnormal colposcopy or a history of ASC or LSIL. For HCII testing, 6 ml of the cell suspension were used. After centrifugation, HPV testing with the high-risk HPV probe (HRHPV) (including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) was performed according to the manufacturer s recommendations. Test results with relative light units (RLU)/cut-off (RLU/CO) values \1.0 were considered negative. Negative controls, positive calibrators, and quality controls always were included in the tests. In 94 specimens (2.28%), HPV testing was repeated after a first negative test result because of TABLE 1 Results of Repeated Human Papillomavirus Testing on 94 Specimens With Previously Negative Test Results HPV test result No. of test % Positive 50/ Negative 44/ HPV indicates human papillomavirus. evident discordance with cytology results. Discordant cases were defined by a consensus group as women who had negative HRHPV test results and obviously abnormal epithelial cells, all strongly suggestive of ASC, cannot rule out high-grade SIL (HSIL) or SIL. The second test was performed using the same protocol as the first test. In 90 specimens, however, testing was also performed using the low-risk HPV (LRHPV) probe to exclude a pure low-risk HPV infection. All women had at least cytologic follow-up. Thirteen women also had histologic follow-up. In situ hybridization with the Inform HRHPV probe cocktail (Ventana Medical Systems, Tucson, Ariz; including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 68, and 70) was performed according to the manufacturer s specifications on histologic specimens of high-grade lesions (cervical intraepithelial neoplasia type 2 or worse [CIN21]) that showed a persistently negative HPV test results with HCII on LBC. Frequencies and percentages were computed for women who had abnormal cytology despite a negative HPV test. The 95% confidence interval (95% CI) of the difference between proportions was constructed using the Newcombe refinement on a Wilson score-based method. 15,16 RESULTS Overall, considering all 4130 LBC specimens, HRHPV testing was positive in 90.9% of LSIL and in 97.8% HSIL. Histologic follow-up was available on 426 women, including 140 women who had negative results, 145 women who had CIN1, and 141 women who had CIN21. In 94 of 4130 LBC specimens (2.28%), HPV testing was repeated after an initial negative test result (RLU/CO \1.0; mean, 0.35) because of an evident discordance with cytology results. In 44 of those 94 retested LBC specimens (46.81%), a negative HRHPV result was confirmed (Table 1); however, in 23 of the 44 specimens (52.27%), LRHPV was positive. The histologic followup of those 44 women showed that 3 women had CIN1, 1 woman had CIN2, and 1 woman had largely invasive squamous cell carcinoma. Cytologically, 6
3 282 CANCER (CANCER CYTOPATHOLOGY) October 25, 2007 / Volume 111 / Number 5 TABLE 2 Histologic Follow-up and Results From the Second Testing With High-risk Human Papillomavirus Second testing Histology CIN1 CIN2 CIN3 AIS Carcinoma Positive Negative Total CIN indicates cervical intraepithelial neoplasia; AIS, adenocarcinoma in situ. TABLE 3 Cytologic Revision of 10 Cytologies With Initially Negative Human Papillomavirus Results Who Had Histologic Follow-up of a High-grade Lesion Patient no. HPV repetition Follow-up Cytologic revision 1 LR2 HR1 CIN3 Scant cellularity, few 2 LR1 HR1 CIN2 Satisfactory for evaluation, numerous 3 LR1 HR1 CIN3 Satisfactory for evaluation, no 4 LR2 HR1 CIN3 Satisfactory for evaluation, inflammation, numerous 5 LR1 HR1 CIN2 Satisfactory for evaluation, high cellularity, numerous 6 LR1 HR1 AIS Satisfactory for evaluation, numerous 7 LR1 HR1 CIN3 Satisfactory for evaluation, numerous 8 LR2 HR1 CIN3 Scant cellularity, few 9 LR2 HR2 Carcinoma Scant cellularity, hemorrhagic, few 10 LR1 HR2 CIN2 Scant cellularity, few cells with slight atypia HPV indicates human papillomavirus; LR indicates low risk; 2, negative; HR, high risk; 1, positive; CIN, cervical intraepithelial neoplasia; AIS, adenocarcinoma in situ. additional women showed LSIL in follow-up. All other women had negative follow-up. Two of the women with CIN1 and the 1 woman with CIN2 had positive results for LRHPV. In situ hybridization with HRHPV probes on the histologic specimens from the women who had persistently HCII-negative squamous cell carcinoma and CIN2 was positive with a typical, dot-like, nuclear pattern. In 50 of 94 specimens (53.19%) who had a repeat HPV test, HRHPV results changed to positive (Table 2). In 21 specimens (42%), HRHPV was associated with a positive LRHPV result. In 21 samples (42%), the HRHPV-RLU value at the second test was [1000; and, in 31 women (62%), the second test value was [500. There was an RLU/CO ratio [2.5 in 33 specimens (66%). The mean RLU/CO value of the 17 samples who had an RLU/CO value \2.5 was In the histologic follow-up of this group, there were 2 women with CIN2, 5 women with CIN3, and an adenocarcinoma in situ. Overall, all but 1 women with CIN21 had an RLU/CO value [2.5 (mean, 488,65 RLU/CO) on a repeat test. One woman with CIN2 had an RLU/CO value of Overall, histologic follow-up identified a dysplastic lesion in 13 of 94 initially HPV-negative cases (13.83%), including 10 high-grade lesions (CIN21) (Table 2). Eight of 10 women (80%) with CIN21 had positive HRHPV results at the second testing. The 2 women with high-grade lesions in which negative HRHPV results were was confirmed included 1 woman who had invasive squamous cell carcinoma with few neoplastic cells in a highly hemorrhagic and necrotic background and 1 woman who had CIN2 with cytologically only very few, slightly dysplastic cells that had been classified as LSIL and was positive for LRHPV (Table 3). At the initial testing, 2.28% of LBC results (95% CI, %) showed abnormal cytology despite a negative HPV result. After repeated HPV testing, the overall percentage was reduced to 1.07% (95% CI, %), with a difference (21.21%) that differed statistically significantly from zero (P \.0001; 95% CI, 21.59% to 20.89%). DISCUSSION The results from this study indicated that HPV testing with HCII on ThinPrep residual cell suspension is mostly reliable but may be afflicted by some falsenegative results, although only a few of those results have potential clinical significance. However, repeat testing in doubtful cases can reduce significantly the number of false-negative results. In fact, of 4130 specimens, 2.28% showed an abnormal cytology despite a negative HPV test; and, after repeated testing, the overall percentage was reduced to 1.07%. Eight of 10 CIN21 cases changed to HPV-positive at the second test, and 7 of those specimens showed an RLU/CO ratio well over the retest zone, which included values between 1 and Among the women who had persistently HPVnegative results, only 2 had clinically significant follow-up, and both were characterized by low sample quality and few abnormal cells. The treatment of these women, however, along with the treatment for women who had results that changed to HPV positive at the second testing, would have been delayed
4 CV Cytology With Discordant HPV Testing/Negri et al. 283 if cytology had not been performed at the same time. Although the cause of the persistently HPV-negative CIN1 results obviously was low sample quality, the cause of the first negative HPV result in women who had results that changed to positive at the second testing is more difficult to comprehend. Repeating HPV testing on the same sample may be associated with a reduction of the RLU value, which can lead in some specimens to a false-negative test result. 12 Because most specimens had a clearly positive RLU/CO ratio at the second testing, we conclude that the original viral load already should have been high enough to warrant a clear positive result at the first testing. Furthermore, these cases always were sporadic, and testing was performed together with correctly positive and negative routine cases as well as positive and negative controls. Thus, the most probable explanation for these cases is sporadic human error in performing the test. Because 3 different technicians were involved in HPV testing during the study period, and the false-negative results were distributed uniformly over the time, it is difficult to individuate a part of the manual procedure involving a higher risk of error. In the future, however, it is expected that the introduction of complete automation of the procedure may reduce at least in part the occurrence of such false-negative test results. Because, in the current study, only a selected high-risk population was analyzed, it is difficult to draw conclusions that may apply to a screening setting. Potentially clinically relevant false-negative HPV test results are rare, and the risk of missing highgrade lesions is relatively low. Overall, the percentage of specimens who had CIN21, HRHPV-negative results at the first testing was 0.24%. Because, during the same period, 553 CIN21 lesions were identified at our institution, this would include 1.81% of all clinically relevant lesions. Furthermore, clinical follow-up essentially is driven by cytology in women who have abnormal results. However, from a practical point of view, HPV testing repetition may prevent the misinterpretation as reactive of some women who have an ASC diagnosis with a false-negative HPV test. If cytologists know the HPV test results at the time of cytologic diagnosis, which is the case in many laboratories, a false-negative test result may lead to an underestimation of the lesion and delayed colposcopy. The awareness of possible sources of false-negative HPV tests is important particularly in the context of HPV only-based screening. 18 Our data alone may not support keeping the Papanicolaou test alongside HPV testing for primary screening. However, at least in high-risk settings or in follow-up, HPV testing on LBC specimens has the advantage of allowing an immediate repetition of the test in case of discordant results. Our results indicate that this approach can clarify most false-negative results, also allowing the identification of those tests with inadequate cytologic sampling that should be repeated immediately. REFERENCES 1. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127: Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7: Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103: Kulasingam SL, Hughes JP, Kiviat N, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288: Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283: Sarode VR, Werner C, Gander R, et al. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: focus on age-stratified clinical performance. Cancer (Cancer Cytopathol). 2003;99: Riethmuller D, Gay C, Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol. 1999;8: Cope JU, Hildesheim A, Schiffman MH, et al. Comparison of the Hybrid Capture 2 test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol. 1997;35: Clavel C, Masure M, Putaud I, et al. Hybrid Capture II, a new sensitive test for human papillomavirus detection. Comparison with Hybrid Capture I and PCR results in cervical lesions. J Clin Pathol. 1998;51: Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol. 2005;124: Castle PE, Wheeler CM, Solomon D, et al. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004;122: Negri G, Rigo B, Vittadello F, et al. Human papillomavirus typing with Hybrid Capture II on archived liquid-based cytologic specimens: is HPV typing always reproducible? Am J Clin Pathol. 2004;122: Jastania R, Geddie WR, Chapman W, Boerner S. Characteristics of apparently false-negative Digene Hybrid Capture 2 high-risk HPV DNA testing. Am J Clin Pathol. 2006;125: Zuna RE, Wang SS, Rosenthal DL, et al. Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial
5 284 CANCER (CANCER CYTOPATHOLOGY) October 25, 2007 / Volume 111 / Number 5 Lesions Triage Study (ALTS). Cancer (Cancer Cytopathol). 2005;105: Newcombe R. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17: Newcombe RG, Altman DG. Proporzioni e loro Differenze. In: Altman DG, Machin D, Bryant TN, et al, eds. Statistica Medica. 2nd ed. Torino, Italy: Minerva Medica; 2004: Muldrew KL, Beqaji SH, Han J, et al. Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a retest zone. Am J Clin Pathol. 2007;127: Stoler MH, Castle PE, Solomon D, Shiffman, M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of wellvalidated assays. Am J Clin Pathol. 2007;127:
Very Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests
292 Very Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests Chengquan Zhao, MD 1 Esther Elishaev, MD 1 Ke-Hai Yuan, PhD 2 Jing Yu, MD 1 R. Marshall
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationPerformance of the Aptima High-Risk Human Papillomavirus mrna Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2011, p. 1071 1076 Vol. 49, No. 3 0095-1137/11/$12.00 doi:10.1128/jcm.01674-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Performance
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationPhilip E. Castle, Diane Solomon, Mark Schiffman, Cosette M. Wheeler for the ALTS Group
ARTICLEARTICLESHuman Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities Philip E. Castle, Diane Solomon, Mark Schiffman,
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationWelcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013
THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationCME/SAM. Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results
Anatomic Pathology / HPV-Negative ASC-H Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results David Cohen, MD, R. Marshall Austin, MD,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationComparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer
BJOG: an International Journal of Obstetrics and Gynaecology August 2004, Vol. 111, pp. 842 848 DOI: 1 0. 1111/j.1471-0528.2004.00210.x Comparison of HPV test versus conventional and automation-assisted
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationSetting The setting was secondary care. The economic study was carried out in Italy.
Role of p16(ink4a) expression in identifying CIN2 or more severe lesions among HPVpositive patients referred for colposcopy after abnormal cytology Carozzi F, Cecchini S, Confortini M, Becattini V, Cariaggi
More informationFor the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group
Effects of Age and Human Papilloma Viral Load on Colposcopy Triage: Data From the Randomized Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesion Triage Study
More informationClinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m
Clinical Relevance of HPV Genotyping A New Dimension In Human Papillomavirus Testing Human Papillomavirus: Incidence HPV prevalence was 26.8% for women in US aged 14 59 yrs 1 20 million Americans are currently
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationAbstract. Human papillomavirus (HPV) DNA testing is cost-effective 1-3 (S. Kulasingam, PhD, et al, unpublished Atypical
Anatomic Pathology / HPV DNA DETECTION IN ALTS A Comparison of a Prototype PCR Assay and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus DNA in Women With Equivocal or Mildly Abnormal
More informationOriginal Articles. Squamous Cell Carcinoma of the Cervix. A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice
Original Articles Squamous Cell Carcinoma of the Cervix A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice Ross A. Miller, MD; Lindsay L. Waters, MD; Dina R. Mody, MD; Kimberlee
More informationScreening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck
Screening for Cervical Cancer Grand Rounds 1/16/13 Meggan Linck Cervical Cancer Worldwide 2 nd most common and 5 th deadliest U.S. 8 th most common 80% occur in developing world Median age at diagnosis
More informationHuman papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands Mitchell S Wachtel 1,
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More informationEU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationOriginal Articles. Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
Original Articles Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests? Siavash Azadmanesh Samimi, MD; Roxanne R. Mody, MD;
More informationJean-Christophe Noël and Philippe Simon. 1. Introduction
Analytical Cellular Pathology Volume 2015, Article ID 746502, 4 pages http://dx.doi.org/10.1155/2015/746502 Research Article Limitations on the Detection Rate of High-Risk HPV by Hybrid Capture 2 Methodology
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationBeyond Pap Morphological Triage: p16/ki67 Dual Staining
Moving away from Beyond Pap Morphological Triage: p16/ki67 Dual Staining Nicolas Wentzensen MD, PhD, MS Deputy Chief, Clinical Genetics Branch; Head, Clinical Epidemiology Unit National Cancer Institute
More informationEvaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationCervical Dysplasia and HPV
Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk
More informationHigh-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics, and Clinical Meaning for Cervical Cancer
103 Ivyspring International Publisher Research Paper International Journal of Medical Sciences 2012; 9(1):103-107 High-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics,
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationThe AutoPap Primary Screening System (APSS; Tripath Imaging,
CANCER CYTOPATHOLOGY 129 A Feasibility Study of the Use of the AutoPap Screening System as a Primary Screening and Location-Guided Rescreening Device Massimo Confortini, M.D. 1 Lucia Bonardi, M.D. 1 Paolo
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More informationAn evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme Sherlaw-Johnson C, Philips Z
An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme Sherlaw-Johnson C, Philips Z Record Status This is a critical abstract of an economic
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationGynecologic Oncology
Gynecologic Oncology 115 (2009) 257 261 Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno High-risk HPV DNA detected in less than 2% of over
More informationHPV: cytology and molecular testing
HPV: cytology and molecular testing Human Papillomavirus and how we test for it at Medlab Central Palmerston North for Cervical Cancer prevention and management. Developed by Reem Mustafa Cytology and
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationSupplements to the European Guidelines on Prevention of Cervical Cancer
Asturias, 23 October, 2011 Asturias, 23 October Supplements to the European Guidelines on Prevention of Cervical Cancer M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat
More informationUsefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy
Usefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy Jaume Ordi, MD, PhD 1 ; Amaia Sagasta, MD 1 ; Meritxell Munmany, MD 2 ; Leonardo Rodrıguez-Carunchio, MD 1 ; Aureli Torne,
More informationMolecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution. Mark H. Stoler, MD PSC Symposium USCAP 2008
Molecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution Mark H. Stoler, MD PSC Symposium USCAP 2008 Objectives: This presentation will briefly review the currently
More informationCervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens
Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens 3 Christine Bergeron, MD, PhD Introduction Carcinoma of the cervix is a slow growing cancer, which is preceded by precancerous
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationDetecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
More informationHPV Primary Screening Update. Prof. Vu Ba Quyet Director of NO&G hospital
HPV Primary Screening Update Prof. Vu Ba Quyet Director of NO&G hospital 1 Who can we not worry about? 2 Key questions Who should be screened? Starting age? Ending age? How often? How to manage results?
More informationModernization of your cytology laboratory and Co-Testing Approach for Cervical Screening
Modernization of your cytology laboratory and Co-Testing Approach for Cervical Screening 2 nd ESPC & 27 th IAP-AD annual meeting Dubai - UAE Mousa Al-Abbadi, MD, FIAC, FCAP, CPHQ, CPE Professor of Pathology
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationHPV Testing ASC-US. Jodie Zeke, a nurse practitioner, received initial CE2. 5. By Kim K. Choma, MSN, APN,C
CE2. 5 HOURS Continuing Education By Kim K. Choma, MSN, APN,C & ASC-US HPV Testing When the Pap result is atypical squamous cells of undetermined significance, testing for the human papillomavirus may
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More information